Keyword
in
Collection
Date
to
Houston Voice, No. 1099, November 16, 2001
File 005
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 1099, November 16, 2001 - File 005. 2001-11-16. University of Houston Libraries. University of Houston Digital Library. Web. October 23, 2019. https://digital.lib.uh.edu/collection/montrose/item/781/show/756.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2001-11-16). Houston Voice, No. 1099, November 16, 2001 - File 005. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/781/show/756

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 1099, November 16, 2001 - File 005, 2001-11-16, Montrose Voice, University of Houston Libraries, accessed October 23, 2019, https://digital.lib.uh.edu/collection/montrose/item/781/show/756.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 1099, November 16, 2001
Contributor
  • Weaver, Penny
  • Crain, Chris
Publisher Window Media
Date November 16, 2001
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 005
Transcript NOVEMBER 16, 2001 • HOUSTON VOICE i Aagouron VIRACEPT" (nelfinavir mesylate) Tablets and Oral Powder Information for Patients atatVWKOT*(VI-raHa|itl Genenc Name: netfiraw (nd-FW-fa-imri mesylate FOT IW I feartratfrJ Or Hhm hMMMatafcioncy Wrm (MV) Infection Please read mis information carefully before taking VIRACEPT Also, please read this leaflet each time you renew the prescription, just m case anything has changed This is a summary and not a replacement lor a careful discussion with your doctor. You and your doctor should discuss VIRACEPT when you start taking this medication and al regular checkups You should reman under a doctor's care when taking VIRACEPT and should not change or stoo treatment without first talking with your doctor Alert Find out about medicines that should NOT be taken with WRAC-EPT. Please also read the Section "MEDICINES YOU SHOULD NOT TAKE WITH VIRACEPT" WHAT IS VIRACEPT AND HOW DOCS IT WORK? VIRACEPT is used in combination with other antiretroviral drugs m the treatment of people with human immurodeficiency virus (HM infection. Infection with HfV leads to the destruction of CD4 T relfc whitt tire important to the immune system. After a large number ot C04 cells have been destroyed, me infected person develops acquired immune deficiency syndrome (AIDSi VIRACEPT works by blocking HIV protease ja protein-cutting enzymei. which is required for HTV to multiply VIRACEPT has been shown to significantly reduce the amount ot HIV in the blood. Although VIRACEPT is not a cure for HIV or AIDS. VIRACEPT can help reduce your nsk tor death and illness associated with HIV Patients who took VIRACEPT also had significant increases in the number of CD4 cell count. VWACEPT should be taken together wrth crther arrtretrow^ o»ucjs surras Retrow19 (zidovurjine. AZT), Epiw* 'lamiyjdme. 3TD. or Zerit® istavucAne, d4Ts Taking VIRACEPT in combination with other anbretroviral drugs reduces the amount of HIV hi the body ivira! load) and raises CD4 counts. vmACEPT may be taken by adults, adolescents and children 2 years of age or older. Studies m infants younger man 2 years ot age are now Qking place. DOES VIRACEPT CURE HIV OR AIDS? VIRACEPT is not a cure for HIV infection or AJK. People BiWvj VlrWIPT may still develop opportunistic infections or other conditions associated wim HtV infection. Some ot these conditions are pneumonia, herpes wrus infections. Mycobacterium avium complex i MAO infections and Kaposi's sarcoma There is no proof that VIRACEPT can reduce the risk of transmitting HIV to others through sexual contact or blood contamination WHO SHOULD OR SHOULD NOT TAKE VIRACEPT? Together wrth your doctor, you need to decide whether ■AWCEPT is appropriate tor you. m making your decision, the following should be considered; Allergies: H you turn had a serious allergic reaction to VRACEPT, you must not take VIRACEPT. You should also inform your doctor, nurse, or pharmacist of any known allergies to substances such as other medicines, tocos preservatives, or dyes. If you are pregnant The effects of VIRACEPT on pregnant women or their unborn babies are not known. If you are pregnant or plan to become pregnant, you should tell your doctor before taking VIRACEPT It you are breast-feeding: You should drscuss wtm you ooctor the best way to feed your baby You should be aware that if your baby (toes not already have HIV. there is a chance that it can be transmitted through Oreast-f eedmg Women should not breast-feed if they have HIV. CTNldren: VIRACEPT is available for the treatment of children 2 through 13 years of age with HTV. There s a powder form of VIRACEPT mat can be mixed wrth milk, baby formula, or foods like pudding. Instructions on how to take VRACEPT powder can be found in a later section that discusses how VIRACEPT Oral Powder should be prepared. If you have liver disease: VIRACEPT has not been studied m people wrth liver disease If you have liver disease, you should tell your doctor before taking VIRACEPT. Othaxr medical problems: Certain medical problems may affect the use of VIRACEPT. Some people taking protease inhibitors have developed new or more serious diabetes or high blood sugar Some people with herrxxiniria have had increased bleeding. It is not knc-vm vvhether the pn»e8se hr^^ caused these problems. Be sure to tell your doctor if you have hemophilia types A and S, diabetes mellitus. or an increase in thirst and/or frequent un nation. Changes m body fat have been seen m some patents taking protease nhibrttirs These changes may include xxreased amount of fat m the upper back and neck {'buffalo hump"), breast, and around the trunk. Loss of fat from the face, legs and arms may also happen. The cause and long-term health effects of these conditions are not known at me lime. CAN VIRACEPT BE TAKEN WITH OTHER MED»t*TIONS? VIRACEPT may interact wrth other drugs, including those you take without a prescription You must discuss wrth your doctor any drugs that you are taking or are planning lo take before you lake VIRACEPT Propulsid* (cisapride, for heartburn i Cortlarone* i amtodarone. for irregular heartbeat) Oumidine (for irregular heartbeat], also known as Quiraglute*, CarrJc-ouin®, Quinidex* and others Ergot denvaBves (Catergot* and cithers, for migrane headache) Halcion* (triazolam) Versed* (midazolam) fvtevacor® ffovastabn, for cholesterol towenngi Zocor* (simvastatin, for cholesterol lowering) Taking the above drugs wrth VIRACEPT may cause serious and/or life- threatening adverse events Rifampin* {for tutercutosis). also known as Rimactane®. Rifadin®, Rifater®. or Rifamate® This drug reduces blood levels of VIRACEPT Dose reduction required if you take VTRACEPT with: Mycobutin® (rifabutin, for MAC); you will need to take a lower dose of Mycobutin ftatnobaWbOal Phenytoin (Dilantin® and others) Carbamazepine (Tegretol® and others* These agents may reduce the amount of VTRACEPT in your Dtood and make it less effective Oral cotrr/aceptives (The pill") If you are taking the pill to prevent pregnancy, you should use a different type of contraception since VIRACEPT may reduce the effectiveness of oral contraceptives Special considerations Before you take Viagra® (sildenafil) with VIRACEPT, talk to your doctor about possible drug interactions and side effects If you take Viagra and VIRACEPT together, you may be at increased risk of side effects of Viagra such as tow blood pressure, visual changes, and penile erection fasting more than 4 hours. If an erection lasts longer than 4 hours, you should seek immediate medical assistance to avoid permanent damage to your penis Your doctor can explain these symptoms to you. It is not recommended to take VIRACEPT wim the cholesterol- iowenng drugs Mevacor® fkwastatin) or Zocor® (simvastabn) because of possible drug interactions. There is also an increased nsk of drug interactions between VIRACEPT and Lipitor® (atorvastatin) and Baycol® (cenvastattnj talk to your doctor before you take either ot these cholesterol reducing drugs wtttt VIRACEPT Taking St. John's wort (hypericum perforatum), an herbal product sold as a dietary supplement, or products aintairMng St. John's wort wrth VIRACEPT is not recommended Talk wrth your doctor it you are taking or are planning to take St. John's wort Taking St. John's wort may decrease VIRACEPT levels and lead to increased viral load and possible resistance to VIRACEPT or cross resistance to other antiretroviral drugs. HOW SHOULD VIRACEPT BE TAKEN WITH OTHER ANTI-HIV DRUGS? Taking VIRACEPT together wrth other anti-HIV drugs increases their ability to fight the virus, ft also reduces the oprjortunrty tor resistant viruses to grow Based on your history of taking othef anti-HIV medicine, your doctor will direct you on how to take VIRACEPT and other anti-HIV medicines. These drugs should be taken in a certain order or at specific times. This will depend on how many times a day wch medicine should be taken. It will also depend on whether it should be taken wrth or without food Nucleoside analogues: No drug interaction problems were seen when VWACEPT was given wrth: Retrovir (zidovudine. AZT) Epivir (lamivudine. 3TC) Zent (stavudine. d4Tj Videx® ididanosine ddli If you are taking both Videx (ddl) and VIRACEPT. Videx should be taken without food, on an empty stomach, Therefore, you should take VIRACEPT with food one hour after or more than two hours before you take Videx Nonnucleoside reverse transcriptase inhibitors (NNRTls): When VIRACEPT is taken together wrth Viramune® (nevirapmei Sustiva"' (efavirenzj Other NNRTls VIRACEPT has not been studied wrth other NNRTls When VIRACEPT is taken together wrth: Cnxivan® (indinavir) The amount of bom drugs in your blood may be increased Currently, there are no safety and efficacy data available from the use of mis combination Norvir'" (ritonavir) The amount of VTRACEPT in your blood may be increased. Currently, there are no safety and efficacy data available from me use of mis combination Invirase® (saquinavir) The amount of saquinavir in your blood may be increased Currently, there are no safely and efficacy data available from the use of mis combination WHAT ARE THE SIDE EFRCTS OF VIRACEPT? Uke all medicines, VIRACEPT can cause side effects. Most of the side effects experienced wrth VIRACEPT have been mild to moderate. Diarrhea is the most common side effect in people taking VIRACEPT, and most adult patients had at least mild diarrhea at some point dunng beafmerrt. in clinical studies, about 15-20% of patients receiving VIRACEPT 750 mg (three tablets) three times daily or 1250 mg (five tablets) two times daily had lour or rrxvek»se stools a day In moa cases dianhia i^i be corWolietj using antidiarrheal medicines, such as krwdium* A-D (loperamide) and cithers, which are available without a prescription CHher side effects that occurred in 2% w nxxB or patiexnts i^c^iving VTRACEPT include nausea, gas and rash. There were other skJe effects noted m ctantcaf studies that occurred In less than 2% of patients receiving VIRACEPT However, these side effects may have been due to other drugs that pabents were taking or to the illness itself. Except for oanhea. there were not many differences m side effects in pabents who look VIRACEPT along wrth other drugs compared wrth those who took only the cither drugs For a complete list of side effects, ask your doctor, nurse, or pharmacist. HOW SHOULD I TAKE VIRACEPT' VIRACEPT is available only wrth your doctor's prescription. Your doctor may prescnbe the light blue VIRACEPT Tablets either as 1250 mg (five tablets) taken two times a day or as 750 mg (three tablets) taken three times a day VIRACEPT should always be taken wrth a meal or a light snack. VIRACEPT tablets are film-coated to help make me tablets easier to swallow. Take VIRACEPT exactly as directed by your doctor. Do not increase or decrease any dose or the number of doses per day. Also, take the medicine for the exact period of time that your doctor has instructed. Do not stop taking VIRACEPT without first consulting with your doctor, even If you are feeling better. Only take medicine that has been prescribed specifically tor you. Do not give VIRACEPT to others or take medicine prescribed for someone else. The dosing of VIRACEPT may be different for you than for other patients Follow the directions from yow drxlrx, exa^ as viiiitten on ttie label. The amount of VIRACEPT m me blood should remain somewhal consistent over time Missing doses will cause me concentration of VIRACEPT to decrease, therefore, you should not miss any doses. However, if you mss a dose, you should take the dose as soon as possible and then take your next scheduled dose and future doses as originally scheduled Dosing in adults (including children 14 years of age and older) The recommended adult dose of VIRACEPT is 1250 mg (five tablets) taken two times a day or 750 mg (three tablets) taken three times a day. Each dose should be taken wim a meal or light snack Dosing in children 2 to 13 years of age The VKACEPT dose m children depends on tteir weigrrt. The recammervJed dose is 20 to 30 mgAg (or 9 to 14 mg/poundl per dose, taken three times daily wrth a meal or light snack This can be administered either in tablet form or. m children unable to take tablets, as VIRACEPT Oral Powder. Dose instructions will be provided by the child's doctor. The dose will be given three times daily using the measuring scoop provided, a measunng teaspoon, or one or more tablets depending on the weight and age of me child The amount of oral powder or tablets to be given to a child is described in the chart below Pediatric Ooie to Ba Ad ml mate rod Throe Times Daily Body Weight K| Lb Number of level Sooopt* Number ol level TMipoontt Number of Tablets T to -=8.5 1SS fo <18 5 4 1 8 5 to <10 5 IB 5 to <23 5 t 1/4 10 5 to <12 2310 <26 5 6 1 1/2 12tO<14 26 510 <31 13/4 14!o<!6 31 io <35 8 2 16 to eft 35 to <39 5 9 21/4 18Id<23 39 5 to <50.5 10 21/2 2 ■23 .505 15 3 3-J 3 In measunng oral powder, Ihe scoop or tetispoon should be level * 1 level scoop conlains 50 mg ot VtRACEFT. Use only the scoop provided wim your VIRACEPT bottle 11 level teaspoon contains 200 mg of VIRACEPT Note: A measuring teaspoon used for dispensing medication should be used for rneasuring VIRACEPT Oral Powder. Ask your pharmacist to make sure you have a medication dispensing teaspoon. How should VIRACEPT Oral Powder be prepared? The oral powder may be mixed with a small amount of water, milk, formula, soy formula, soy milk, dietary supplements, or dairy foods such as pudding or ice cream. Once mixed, me entire amount must be taken to obtain the full dose Do not mix the powder with any acidic (cod or juice, such as orange or grapefruit juice, apple juice, or apple sauce, because mis may create a bitter taste. Once the powder is mixed, it may be stored at room temperature or refrigerated for up to 6 hours. Do not heat the mixed dose once it has been prepared Do not add water fo bottles of oral powder VIRACEPT powder is supplied wim a scoop for measuring For help in determining the exact dose of powder for your child, please ask your doctor, nurse, or pharmacist. VIRACEPT Oral Powder contains aspartame, a low-calorie sweetener, and therefore should not be taken by children wrth phenylketonuna (PKU) HOW SHOULD VIRACEPT BE STORED? Keep VIRACEPT and all other medicines out of me reach of children Keep bottle closed and store at room temperature (between 59°F and 86T) away from sources of moisture such as a sink or other damp place. Heat and moisture may reduce the effectiveness of VIRACEPT Do not keep medicine that ts out of date or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children. Discuss all questions about your health wrth your doctor. If you have questions about VIRACEPT or any other medication you are taking, ask your doctor, nurse, or pharmacist. You can also call 1.888.VIRACEPT (1.888.847.2237) toll free. ^H1.8ffiV1RACEPT VWACEPT and Agouron are registered trademarks of Agouron fmarmaceutjcals, Inc. Crjpyright O2001. Agouron Pharmaceuticals. Inc All rights reserved. Agouron. PtmmmC»MaCmm.i^C. Agouron r-tiairnaceuticals Inc La Joila. California. 92037, USA L203-0001 PP1 Rev. 01/25/01
File Name uhlib_31485329_n1099_004.jpg